Category Archives: News and Events

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 15, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS(TM) Patient

IMAGES BELOW] 11-month sustained complete resolution of lung metastasis observed in Bria-OTS Phase 1/2a metastatic ...

Eleven clinical trials that will shape medicine in 2026″ – BriaCell Phase 3 Trial Featured in Nature Medicine

Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited ...

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Symposium ...

BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Over 230 patients screened and over 160 patients enrolled in BriaCell’s pivotal Phase 3 study ...

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Three poster presentations at the San Antonio Breast Cancer Symposium (SABCS), now available and to ...

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight ...

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Collaboration uses Receptor AI’s platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, ...

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Three BriaCell poster presentations include updated key biomarker data from BriaCell’s pivotal Phase 3 study ...